Breast cancer

Cancer Control

Volumn 8, Issue 6 SUPPL., 2001, Pages 54-61

  Carlson, R W ^a   Edge, S B ^a   Theriault, R L ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

BREAST CANCER; CANCER STAGING; CANCER THERAPY; CONFERENCE PAPER; HUMAN; LYMPH NODE IRRADIATION; MAMMOGRAPHY; MASTECTOMY; PRACTICE GUIDELINE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; LYMPH NODE METASTASIS; METHODOLOGY; PAGET NIPPLE DISEASE; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMAN; LYMPHATIC METASTASIS; MASTECTOMY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME;

EID: 0035513088     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. NCCN breast cancer practice guidelines
2. A prognostic index for ductal carcinoma in situ of the breast
3. The influence of margin width on local control of ductal carcinoma in situ of the breast
4. Benefits of irradiation for DCIS: A Pyrrhic victory
5. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
6. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of protocol B-17: Intraductal carcinoma
7. Radiotherapy in breast- conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853
8. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
9. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials
10. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials
11. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy
12. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: Experience of the Eastern Cooperative Oncology Group
13. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology
14. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
15. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
16. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
17. Tamoxifen for early breast cancer: An overview of the randomised trials
18. HER2. A 'predictive factor' ready to use in the daily management of breast cancer patients?
19. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
20. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
21. HER-2/neu as a predictive marker of response to breast cancer therapy
22. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
23. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay
24. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
25. The role of HER-2 expression in predicting response to therapy in breast cancer
26. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients
27. NIH consensus panel recommends a range of adjuvant therapies for women with breast cancer
28. Polychemotherapy for early breast cancer: An overview of the randomised trials
29. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
30. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables
31. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
32. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
33. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23
34. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma
35. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
36. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
37. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
38. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
39. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer
40. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
41. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-Year follow-up results of French Adjuvant Study Group 05 randomized trial
42. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial
43. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up
44. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines